Edgewise Therapeutics (EWTX) free cash flow

Free cash flow · fiscal 2025
-$144.07M

Edgewise Therapeutics (EWTX) generated free cash flow of -$144.07M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$110.34M. Figures as of 18 Nov 2026, 12:34 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
-$144.07M
Highest on record
-$14.84Mfiscal 2020
Lowest on record
-$144.07Mfiscal 2025
Fiscal years on record
62020–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Edgewise Therapeutics free cash flow, in more detail

Across the 6 fiscal years on record (2020–2025), the highest was -$14.84M in fiscal 2020 and the lowest -$144.07M in fiscal 2025.

History · 6 fiscal years

Free cash flow by fiscal year

Edgewise Therapeutics free cash flow, year by year

Edgewise Therapeutics (EWTX) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025-$144.07M—
2024-$110.34M—
2023-$97.69M—
2022-$58.18M—
2021-$34.18M—
2020-$14.84M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Edgewise Therapeutics and comparable companies
CompanyFree cash flowFiscal year
Concentra Group Holdings Parent CON$197.06M2025
Merit Medical Systems MMSI$212.54M2025
Edgewise Therapeutics EWTX-$144.07M2025
LivaNova LIVN$173.29M2025
Ionis Pharmaceuticals IONS-$325.67M2025
Dianthus Therapeutics DNTH-$129.27M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on EWTX

Edgewise Therapeutics, figure by figure

Edgewise Therapeutics (EWTX) overview: price, valuation and scorecardAll health care companies by market value

Edgewise Therapeutics free cash flow: questions and answers

What is Edgewise Therapeutics's free cash flow?

Edgewise Therapeutics (EWTX) generated free cash flow of -$144.07M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$110.34M.

What are the highest and lowest free cash flow figures on record for Edgewise Therapeutics?

Across the 6 fiscal years on record (2020–2025), the highest was -$14.84M in fiscal 2020 and the lowest -$144.07M in fiscal 2025.

How is Edgewise Therapeutics's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Edgewise Therapeutics it is on record here for 6 fiscal years, 2020 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Edgewise Therapeutics (EWTX) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/EWTX/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.